Director/PDMR Shareholding
Summary by AI BETAClose X
25 June 2026
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces the award of nil-cost share options to the following Directors and persons discharging managerial responsibilities (PDMRs) of the Company (the "Awards") under the existing Advanced Medical Solutions Long Term Incentive Plan (the "LTIP").
The Awards were previously approved by the Company's Remuneration Committee and were due to be released in April 2026 in accordance with the Company's annual Executive remuneration cycle. Following today's publication of inside information in relation to the recommended cash acquisition of AMS by H.B. Fuller Medical Adhesive Technologies Inc. ("Bidco", a wholly-owned subsidiary of H.B. Fuller Company), the grant of the Awards has become effective today.
The vesting of these Awards is subject to the achievement of certain performance criteria for the three years prior to vesting. The performance criteria under the LTIP scheme is split equally between Earnings Per Share (EPS) achievement against target and Total Shareholder Return (TSR) against a comparator group. The recipients are required to hold the Awards for a period of two years following vesting.
Details of the impact of the Acquisition on all AMS Share Plans (including the Awards) and any associated proposals are summarised in the Co-operation Agreement between the Company and Bidco, and will be set out in the Scheme Document, and in separate letters to be sent to participants in all AMS Share Plans.
Capitalised terms used but not defined in this announcement have the same meaning as set out in today's announcement of the recommended cash acquisition of AMS by Bidco.
|
PDMRs |
AMS Shares subject to Awards granted |
|
Chris Meredith, Chief Executive Officer |
422,941 |
|
Eddie Johnson, Chief Financial Officer |
174,568 |
The notification below, made in accordance with the requirements of the Market Abuse Regulation no 596/2014 (incorporated into UK law by virtue of the European Union (Withdrawal) Act 2018 as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019), provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Chris Meredith |
||||
|
2. |
Reason for the notification |
||||
|
a) |
Position/status: Chief Executive Officer |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Options over ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: - Grant of Awards under the Advanced Medical Solutions Long Term Incentive Plan 2014 |
||||
|
c) |
Price(s) and volume(s):
|
||||
|
d) |
Aggregated information: Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 25 June 2026 |
||||
|
f) |
Place of the transaction: Outside of a trading venue, XOFF |
|
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Eddie Johnson |
||||
|
2. |
Reason for the notification |
||||
|
a) |
Position/status: Chief Financial Officer |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Options over ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: - Grant of Awards under the Advanced Medical Solutions Long Term Incentive Plan 2014 |
||||
|
c) |
Price(s) and volume(s):
|
||||
|
d) |
Aggregated information: Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 25 June 2026 |
||||
|
f) |
Place of the transaction: Outside of a trading venue, XOFF |
- End -
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: +44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations |
|
|
|
|
|
Optimum Strategic Communications |
Tel: +44 (0) 20 4566 8543 |
|
Mary Clark / Nick Bastin / Isabelle Abdou |
|
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: +44 (0) 20 7597 5970 |
|
Gary Clarence / Harry Hargreaves / Nick Prowting |
|
|
Berenberg (Joint Broker) |
Tel: +44 (0)20 3207 7800 |
|
Toby Flaux / Detlir Elezi |
|
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.
AMS's products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,800 employees. For more information, please see www.admedsol.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 12 hours ago Luceco
- 12 hours ago Helios Towers
- 13 hours ago Wise Class A
- 13 hours ago EDX Medical Group Plc
- 13 hours ago Naked Wines